Table 2. Sensitivity at 95% and 98% specificity of pancreatic cancer detection by time between blood draw and diagnosis, for crude marker measurements and with adjustments for case-control matching factorsa.
| Lag-time (months) | threshold 95 crude | SE95 (95% CI) crude | SE95 (95% CI) adjusted | threshold 98 crude | SE98 (95% CI) crude | SE98 (95% CI) adjusteda |
|---|---|---|---|---|---|---|
| CA19-9 (U/mL) | ||||||
| ≤6 | 29.2 | 0.57 (0.30-0.81) | 0.54 (0.36-0.64) | 38.0 | 0.50 (0.23-0.77) | 0.50 (0.29-0.57) |
| >6-18 | 29.2 | 0.32 (0.16-0.54) | 0.34 (0.25-0.46) | 38.0 | 0.29 (0.12-0.53) | 0.27 (0.18-0.36) |
| ≤18 | 29.2 | 0.40 (0.24-0.59) | 0.39 (0.36–0.43) | 38.0 | 0.36 (0.19-0.58) | 0.35 (0.31-0.38) |
| >18-36 | 29.2 | 0.12 (0.04-0.28) | 0.14 (0.07-0.21) | 38.0 | 0.07 (0.02-0.24) | 0.10 (0.05-0.16) |
| >36-60 | 29.2 | 0.07 (0.02-0.18) | 0.07 (0.03-0.14) | 38.0 | 0.03 (0.01-0.13) | 0.04 (0.01-0.10) |
| ApoA2-ATQ/AT (μg/mL) | ||||||
| ≤6 | 30.3 | 0.21 (0.07-0.52) | 0.27 (0.07-0.43) | 27.7 | 0.14 (0.03-0.47) | 0.19 (0.07-0.35) |
| >6-18 | 30.3 | 0.25 (0.11-0.47) | 0.22 (0.11-0.32) | 27.7 | 0.21 (0.08-0.46) | 0.15 (0.04-0.21) |
| ≤18 | 30.3 | 0.24 (0.12-0.42) | 0.23 (0.12-0.31) | 27.7 | 0.19 (0.08-0.40) | 0.16 (0.07-0.21) |
| >18-36 | 30.3 | 0.05 (0.01-0.19) | 0.09 (0.02-0.16) | 27.7 | 0.05 (0.01-0.20) | 0.05 (0.00-0.09) |
| >36-60 | 30.3 | 0.07 (0.02-0.18) | 0.18 (0.03-0.14) | 27.7 | 0.04 (0.01-0.15) | 0.05 (0.00-0.10) |
a
adjustment factors were: study recruitment country, sex, age at blood collection, and exogenous hormone use (contraceptive OC/HRT) at time of blood donation
Note: SE95 = sensitivity at 95% specificity; SE98 = sensitivity at 98% specificity; CI = confidence interval